{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:32:50Z","timestamp":1789975970252,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":4475,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2003,9]]},"DOI":"10.1046\/j.1523-1747.2003.12413.x","type":"journal-article","created":{"date-parts":[[2003,8,19]],"date-time":"2003-08-19T09:12:48Z","timestamp":1061284368000},"page":"550-556","source":"Crossref","is-referenced-by-count":89,"title":["Cytotoxic T Lymphocyte Reactivity to gp100, MelanA\/MART-1, and Tyrosinase, in HLA-A2-Positive Vitiligo Patients"],"prefix":"10.1016","volume":"121","author":[{"given":"Rochelle L.","family":"Mandelcorn-Monson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Shear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryaprakash","family":"Sambhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Spaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"DeBenedette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.1711700209","article-title":"An immunohistological study of cutaneous lymphocytes in vitiligo","volume":"0","author":"Badri","year":"1993","journal-title":"J Pathol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0015","first-page":"23","article-title":"Vitiligo is associated with HLA-A2 and HLA-Dw7 in the Slovak populations","volume":"42","author":"Buc","year":"1996","journal-title":"Folia Biol (Praha)"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.1985.tb01532.x","article-title":"The significance of vitiligo antibodies","volume":"12","author":"Bystryn","year":"1985","journal-title":"J Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0025","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/archderm.1987.01660320095019","article-title":"Prognostic significance of hypopigmentation in malignant melanoma","volume":"123","author":"Bystryn","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0923-1811(99)00029-8","article-title":"Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo","volume":"21","author":"Caixia","year":"1999","journal-title":"J Dermatol Sci"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0035","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-4362.1996.tb00654.x","article-title":"Vitiligo associated with metastatic malignant melanoma","volume":"35","author":"Cavallari","year":"1996","journal-title":"Int J Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0040","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/1523-1747.ep12289743","article-title":"Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo","volume":"108","author":"Yu","year":"1997","journal-title":"J Invest Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.180.1.35","article-title":"A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas","volume":"180","author":"Coulie","year":"1994","journal-title":"J Exp Med"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0050","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/archderm.1995.01690150078015","article-title":"Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells","volume":"131","author":"Cui","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0055","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0198-8859(99)00155-X","article-title":"Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance of A*02011 and identification of HLA-A*0231","volume":"61","author":"Ellis","year":"2000","journal-title":"Hum Immunol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0060","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"van Elsas","year":"1999","journal-title":"J Exp Med"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0065","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/326881a0","article-title":"Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2","volume":"326","author":"Gotch","year":"1987","journal-title":"Nature"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00002371-200001000-00004","article-title":"Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma","volume":"23","author":"Kawakami","year":"2000","journal-title":"J Immunother"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2249.1998.00746.x","article-title":"Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: A sensitive and quantitative radioimmunoassay (RIA)","volume":"114","author":"Kemp","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/08916930108994127","article-title":"Autoimmune aspects of vitiligo","volume":"34","author":"Kemp","year":"2001","journal-title":"Autoimmunity"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0085","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0190-9622(98)70194-X","article-title":"Vitiligo","volume":"38","author":"Kovacs","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0090","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/archderm.1984.01650410073019","article-title":"Vitiligo treated with topical clobetasol propionate","volume":"120","author":"Kumari","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0095","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1523-1747.2001.01363.x","article-title":"HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA\/MART1","volume":"116","author":"Lang","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0100","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/9525","article-title":"Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients","volume":"5","author":"Lee","year":"1999","journal-title":"Nat Med"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0105","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archderm.1993.01680290066010","article-title":"Pattern of familial aggregation of vitiligo","volume":"129","author":"Majumder","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-4362.1996.tb01609.x","article-title":"Organ-specific autoantibodies in vitiligo patients and their relatives","volume":"35","author":"Mandry","year":"1996","journal-title":"Int J Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1084\/jem.158.1.246","article-title":"Antibodies to normal human melanocytes in vitiligo","volume":"158","author":"Naughton","year":"1983","journal-title":"J Exp Med"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0120","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0125","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.4049\/jimmunol.165.4.2287","article-title":"Status of activation of circulating vaccine-elicited CD8+ T cells","volume":"165","author":"Nielsen","year":"2000","journal-title":"J Immunol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0130","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0190-9622(83)70182-9","article-title":"Vitiligo in patients with metastatic melanoma: A good prognostic sign","volume":"9","author":"Nordlund","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0135","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.188.6.1203","article-title":"High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo","volume":"188","author":"Ogg","year":"1998","journal-title":"J Exp Med"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0140","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1046\/j.1523-1747.2001.01408.x","article-title":"Specific cytotoxic T lymphocyte responses against Melan-A\/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex\/peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo","volume":"117","author":"Palermo","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0198-8859(81)90065-3","article-title":"Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28","volume":"3","author":"Parham","year":"1981","journal-title":"Hum Immunol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0150","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.4049\/jimmunol.149.11.3580","article-title":"Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2","volume":"149","author":"Parker","year":"1992","journal-title":"J Immunol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0155","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.4049\/jimmunol.157.6.2539","article-title":"Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues","volume":"157","author":"Parkhurst","year":"1996","journal-title":"J Immunol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0160","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archderm.1976.01630350007002","article-title":"Photochemotherapy of vitiligo. Use of orally administered psoralens and a high-intensity long-wave ultraviolet light system","volume":"112","author":"Parrish","year":"1976","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0165","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1084\/jem.190.5.705","article-title":"High frequencies of naive Melan-A\/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals","volume":"190","author":"Pittet","year":"1999","journal-title":"J Exp Med"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002371-199601000-00009","article-title":"Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy","volume":"19","author":"Rosenberg","year":"1996","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0175","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000247240","article-title":"Histocompatibility antigens in vitiligo. Hamburg study on 102 patients from northern Germany","volume":"187","author":"Schallreuter","year":"1993","journal-title":"Dermatology"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1084\/jem.183.2.527","article-title":"An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins","volume":"183","author":"Skipper","year":"1996","journal-title":"J Exp Med"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0185","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(94)91709-4","article-title":"The role of tyrosinase in autoimmune vitiligo","volume":"344","author":"Song","year":"1994","journal-title":"Lancet"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0190","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archderm.1983.01650330014006","article-title":"Topically administered fluorouracil in vitiligo","volume":"119","author":"Tsuji","year":"1983","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0195","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.4049\/jimmunol.160.4.1750","article-title":"Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A\/MART-1 immunodominant peptide analogues","volume":"160","author":"Valmori","year":"1998","journal-title":"J Immunol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0200","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.4049\/jimmunol.154.8.3991","article-title":"CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells","volume":"154","author":"Visseren","year":"1995","journal-title":"J Immunol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0205","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/labinvest.3780138","article-title":"Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site","volume":"80","author":"van den Wijngaard","year":"2000","journal-title":"Lab Invest"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0210","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1128\/JVI.70.11.7569-7579.1996","article-title":"The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65. Frequency, specificity, and T-cell receptor usage of pp65-specific CTL","volume":"70","author":"Wills","year":"1996","journal-title":"J Virol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0215","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/eji.1830240340","article-title":"Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes","volume":"24","author":"Wolfel","year":"1994","journal-title":"Eur J Immunol"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0220","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1084\/jem.192.11.1637","article-title":"Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo","volume":"192","author":"Yee","year":"2000","journal-title":"J Exp Med"},{"key":"10.1046\/j.1523-1747.2003.12413.x_bb0225","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0923-1811(98)00070-X","article-title":"Serum concentration of the soluble interleukin-2 receptor in vitiligo patients","volume":"19","author":"Yeo","year":"1999","journal-title":"J Dermatol Sci"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15304139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15304139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T15:28:47Z","timestamp":1704900527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X15304139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["S0022202X15304139"],"URL":"https:\/\/doi.org\/10.1046\/j.1523-1747.2003.12413.x","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}